Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia - Wikidata - wikimedia - TriplyDB

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

http://www.wikidata.org/entity/Q33388196

about

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: my way.Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea.Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus New Therapeutic Approaches for Waldenstrom Macroglobulinemia Novel agents in Waldenström macroglobulinemia.Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy.Novel agents in Waldenstrom Macroglobulinemia.How to manage Waldenstrom's macroglobulinemia.Bortezomib for the treatment of non-Hodgkin's lymphoma Bortezomib: friend or foe of hemolytic anemia?New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma.Novel treatment regimens for Waldenström's macroglobulinemia.Emerging drugs for Waldenström's macroglobulinemia.Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.Hematopoietic cell transplantation for Waldenström macroglobulinemia.Targeting the bone marrow in Waldenstrom macroglobulinemia.Risk stratification in Waldenström macroglobulinemia.Waldenström macroglobulinaemia: the key questions.Novel treatment options for Waldenström macroglobulinemia Waldenström macroglobulinemia: from biology to treatment.Current and future therapeutic approach for Waldenström's macroglobulinemia.Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.Waldenström Macroglobulinemia: Review of Pathogenesis and Management.Current options to manage Waldenström's macroglobulinemia.Excellent long-term survival of 170 patients with Waldenström's macroglobulinemia treated in private oncology practices and a university hospital.Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

P2860

Q26776391-88CF274F-6F21-4A3D-8EC3-B5CD0AF0DB99 Q27314737-7D89649B-B309-44C3-BF11-E8F292FD17E9 Q28290236-3840AFEA-32E4-400D-8B62-38F19ED97539 Q28291793-B77170A9-CBB1-46AB-8DD8-824077BBDF58 Q28484018-85EFE342-A0B9-42B9-A871-CEFB74EE2AF0 Q33395066-67466048-4E63-4A36-8BD1-5DA62F2B9098 Q33400780-F2177AFA-25AE-4F67-90EC-CC8C48952B37 Q33402669-76F2A605-3653-499C-934F-7169F628FEAD Q33408517-E4E3CDFB-A68E-4980-9CEC-C864B0FFC9DF Q33421444-44BBFA15-3EF7-4044-BD58-85587ECE6918 Q33438490-5E8FEDA8-0C66-435B-A0EF-D977993C6561 Q33786873-4EC86B74-7F34-4026-A7F3-1BD4803F8FEA Q34106817-01618A05-8A9F-4E16-87F4-75C148978F02 Q35176177-A54FDCEF-AB70-407C-8A51-59CE90CA8630 Q35429544-76115599-5834-4069-BC2C-73FD0DDA8BE1 Q35868965-64DD3274-3588-4907-99CF-96BC237B69BE Q36117791-0FE3C00C-B111-4F70-ADBE-0D9BB39EA353 Q36764811-96732A08-C4D6-4761-9E3C-A9BDC83EB808 Q36868056-47B52A7D-22AB-42E4-90F4-C7771D4E80F0 Q37766378-28F972DB-7CCF-4B59-95BD-93ACBBAB415D Q37786616-2CF5FFBF-0852-4A41-96A3-E03C17E0F47F Q37810101-075E7F81-BEAB-4AE3-8712-A921AA37F225 Q37847176-63DD67FC-FC8E-4C57-8BED-F0AB0D017930 Q37854714-ABA28168-83FB-497F-B066-539631373F46 Q37875673-83371C07-32F5-4301-ABDA-6BEB637EA3CE Q37950586-60127522-507B-403B-9332-DDAE3ED9692A Q37999886-56D8C45F-D4AD-4FA4-87A2-C61219722FD1 Q38104808-10BB5BF6-EC07-4127-A2B7-D1E7710F6A4D Q38167433-022F4DD1-7641-49E5-B0FD-302266232AE5 Q38176969-39D3DFFF-BFC8-4D65-82E1-D549BF9AE7B5 Q38206820-A7439076-FD43-4044-9073-9760E3147FE3 Q38551391-E21118BA-50DF-473E-B763-3A98C69BAE9D Q38635212-28B19B0C-F593-42FC-AE12-F3434093EEC8 Q38970612-D2B0DDAB-C954-4DCE-B3C2-BFB2D70C45CF Q39044362-5B6D6E0C-72C7-4596-A679-0BDEEB1F5B9B Q39214071-9913E280-F6C8-4FAD-ABBA-9FACEDCCABE9 Q39358109-972F8CB2-804E-44C8-82A6-B45E754A4CDC Q40056963-30FCAD59-55FE-42B8-ABD2-C065E7BE0342 Q40773209-22C23D07-FA8F-44C8-89E5-40DE8951D419 Q42355443-1ED81EED-48B6-426B-98DE-31DFCFA9FC36

P2860

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

http://www.wikidata.org/entity/Q33388196

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase II trial of weekly borte ...... Waldenstrom macroglobulinemia

@ast

Phase II trial of weekly borte ...... Waldenstrom macroglobulinemia

@en

type

label

Phase II trial of weekly borte ...... Waldenstrom macroglobulinemia

@ast

Phase II trial of weekly borte ...... Waldenstrom macroglobulinemia

@en

prefLabel

Phase II trial of weekly borte ...... Waldenstrom macroglobulinemia

@ast

Phase II trial of weekly borte ...... Waldenstrom macroglobulinemia

@en

P1433

Q33388196-47462B77-084A-40B5-924B-7662E0CC8774

P1476

Q33388196-56AF35A3-41ED-4EA3-965C-AA4628B82992

P2093

Q33388196-2C45F8E6-F817-45B8-B50D-8043E701ADF5

Q33388196-305B1063-0270-434D-B1F8-E6507BBE77D3

Q33388196-3C8BC7AB-634A-4A1F-AE03-E4315814E3F5

Q33388196-499B9F03-6766-44F8-A816-342D009A3D6B

Q33388196-5CA0511D-5347-4434-A158-5CB5B860B083

Q33388196-62FC4895-4149-4EB0-8A2D-6C4905AACF22

Q33388196-8577EF5E-A08E-489A-8F68-BA5CED36AE65

Q33388196-8C419EE2-B380-46B1-ABA6-C72704EEF72B

Q33388196-A2D258AF-C2CD-4993-976C-BD0DA87F6BE3

Q33388196-AE695A68-62F2-4E7C-963E-CF93F4DD374D

P2860

Q33388196-00151F6A-AF78-471B-A383-DE0241023F61

Q33388196-05A8B26E-25D1-44E6-9282-66AED48FB012

Q33388196-15C595CA-806D-4C78-9DD8-47C48D2C21FF

Q33388196-167C108A-43E3-46A3-8321-EEE2AFEBABC6

Q33388196-28228A27-8771-473E-8983-BEF478E0E60D

Q33388196-394E8180-729F-4E97-9B9D-5D1E30ADD8E3

Q33388196-3A628260-93C5-42D9-BEA8-53AEA7A0C1D1

Q33388196-3EDBAEF7-27AA-484F-9876-E9371FC6766A

Q33388196-476A8BC9-8CBF-4768-B734-24D814344460

Q33388196-4CD6A617-DC39-4B0C-9538-FD3270716EBA

P304

Q33388196-5A9BF80E-10DF-4491-97C7-022710C68A32

P31

Q33388196-B505A562-3BF8-4FCE-86A7-64EF735B597D

P356

Q33388196-1F0D9E92-949E-497D-8DCB-CC3E41117081

P407

Q33388196-8685587F-8796-4AA9-8E61-BC55626F88E4

P433

Q33388196-09893557-21FE-4A1A-92B2-77AD8FBAFFFC

P478

Q33388196-3527BC3A-17AA-485E-9D09-FF131E734D61

P50

Q33388196-41D95FCC-2125-43BD-9822-443DB60DAF82

Q33388196-9DE720DE-69D1-49DB-BCAE-48D3C6DE25CC

Q33388196-CD33EA83-11B1-428B-9B2B-62A6B3AA5662

Q33388196-D9179CE4-A875-4F39-AC83-C7AD4D026282

P577

Q33388196-E61C2F6E-CBAD-4B4A-A3F5-1EC56717790A

P5875

Q33388196-8751A3BD-9D39-4290-99AC-B63662AB94B4

P698

Q33388196-62A9836C-4580-493C-8827-312F64E88166

P921

Q33388196-49804269-0A11-4A9D-8D61-F9E63C8D2278

P932

Q33388196-E0D21075-F351-4BE1-9956-4C46A8533483

P356

JCO.2009.25.3237

P1433

Journal of Clinical Oncology

P1476

Phase II trial of weekly borte ...... Waldenstrom macroglobulinemia

@en

P2093

Amy Sam

http://www.w3.org/2001/XMLSchema#string

Ashraf Badros

http://www.w3.org/2001/XMLSchema#string

Diane Warren

http://www.w3.org/2001/XMLSchema#string

Edie Weller

http://www.w3.org/2001/XMLSchema#string

Fangxin Hong

http://www.w3.org/2001/XMLSchema#string

Irene M Ghobrial

http://www.w3.org/2001/XMLSchema#string

Janet Kunsman

http://www.w3.org/2001/XMLSchema#string

Jeffrey Matous

http://www.w3.org/2001/XMLSchema#string

Meghan Rourke

http://www.w3.org/2001/XMLSchema#string

Renee Leduc

http://www.w3.org/2001/XMLSchema#string

P2860

Waldenström macroglobulinemia

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Diagnosis and management of Waldenstrom's macroglobulinemia

Targeting NF-kappaB in Waldenstrom macroglobulinemia

Signaling to NF-kappaB

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

Waldenström's macroglobulinemia: clinical features, complications, and management.

P304

1422-1428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.25.3237

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Swaminathan Padmanabhan

Kenneth C Anderson

Paul G Richardson

P577

2010-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41416923

http://www.w3.org/2001/XMLSchema#string

P698

20142586

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2834499

http://www.w3.org/2001/XMLSchema#string